Constipation Drug Slows Kidney Disease in 150-Patient Trial

Scientists stumbled onto a surprising way to protect failing kidneys while studying something far simpler: constipation relief.

Researchers at Tohoku University Graduate School of Medicine in Japan tested whether lubiprostone, a medication normally prescribed for constipation, could slow chronic kidney disease. The results from 150 patients revealed something remarkable: the drug actually helped preserve kidney function.

Chronic kidney disease affects hundreds of millions of people worldwide and remains one of the leading causes of kidney failure. As the disease worsens, many patients eventually need dialysis to survive. Current treatments can slow damage, but no approved medications directly restore kidney function.

The research team noticed that constipation frequently accompanies kidney disease and wondered if the two problems were connected. They launched a clinical trial across nine medical institutions in Japan, giving patients either lubiprostone or a placebo for 24 weeks.

Patients who received the medication showed slower kidney decline compared to those on placebo. Higher doses produced stronger protective effects, with the 16 microgram group showing particularly promising results measured by kidney filtration rates.

The mechanism surprised even the researchers. Lubiprostone changed gut bacteria in ways that boosted production of spermidine, a natural compound linked to healthier mitochondria. Mitochondria power our cells, and when they function better, kidney tissue appears more resistant to damage.

The discovery highlights what scientists call the gut-kidney axis, the complex relationship between intestinal bacteria and kidney health. People with kidney disease often experience imbalances in gut microbes, which contribute to inflammation and harmful compound buildup.

The Ripple Effect

Because lubiprostone is already approved for constipation, it could potentially reach patients faster than developing an entirely new drug from scratch. The team is now planning larger Phase 3 trials to confirm the benefits in broader populations.

The findings may extend beyond kidney disease. Mitochondrial dysfunction plays a role in many chronic illnesses, so researchers are exploring whether similar gut-targeted approaches could help other disorders as well.

For people living with chronic kidney disease, even modest slowing of kidney decline could delay dialysis and meaningfully improve quality of life. The research adds momentum to a growing field focused on how gut bacteria, cellular energy, and chronic disease progression intersect.

Sometimes the best medical breakthroughs come from looking at familiar problems in completely new ways.